INTRODUCTION
============

Osteosarcoma (OS) is the most common primary malignant bone tumor, arising from the malignant transformation of mesenchymal cells, which differentiate towards the formation of osteoid and bone ([@b14-molcell-37-2-118-5]; [@b20-molcell-37-2-118-5]). Conventionally, according to histological features, OS is classified into chondroblastic, osteoblastic and fibroblastic OS ([@b3-molcell-37-2-118-5]). The incidence is higher in adolescents, where it accounts for \>10% of all solid cancers and 20--35% of all malignant primary bone tumors ([@b3-molcell-37-2-118-5]; [@b23-molcell-37-2-118-5]). OS usually arises in the metaphysis of a long extremity bone, most commonly around the knee ([@b3-molcell-37-2-118-5]); it is highly aggressive and mostly metastasizes to the bones and lungs ([@b7-molcell-37-2-118-5]). However, despite the use of aggressive chemotherapeutic treatment strategies, the survival rate of OS patients has still not been improved. Also, the prognosis is very poor, especially in patients with clinically detectable metastasis at diagnosis ([@b32-molcell-37-2-118-5]). Osteosarcoma is usually associated with aggressive behavior and a high degree of local recurrence and metastasis ([@b23-molcell-37-2-118-5]). The most significant negative prognostic factor in the treatment of tumors is the development of metastatic disease. As a result, treating metastatic osteosarcoma remains a challenge for oncologists ([@b20-molcell-37-2-118-5]). Thus, a novel strategy to efficiently inhibit the metastasis of osteosarcoma is highly indispensable.

The extracellular matrix (ECM) contains a series of important cues for tissue homeostasis and morphogenesis ([@b1-molcell-37-2-118-5]). Interactions between cells and the ECM also regulate the ability of a cell to proliferate, migrate, and differentiate ([@b12-molcell-37-2-118-5]). Most ECM glycoproteins promote cell adhesion and cause cytoskeletal reorganization, leading to signals that direct differentiation and promote cell survival ([@b18-molcell-37-2-118-5]). Another class of ECM proteins exists, termed "matricellular" proteins, which function as adaptors and modulators of cell-matrix interactions ([@b24-molcell-37-2-118-5]). These structurally diverse proteins include thrombospondins (TSPs) and tenascins, both of which exhibit highly regulated expression during development and cellular injury ([@b18-molcell-37-2-118-5]).

Tenascins are a family of four multimeric extracellular matrix (ECM) glycoproteins, including tenascin-C, X, R and W ([@b30-molcell-37-2-118-5]). Studies have shown that the matricellular protein tenascin-C (TN-C) is overexpressed in remodeling tissues and tumors ([@b1-molcell-37-2-118-5]). For instance, tenascin-C is highly expressed in glioblastoma multiforme (GBM) ([@b11-molcell-37-2-118-5]) and giant cell tumors of bones ([@b21-molcell-37-2-118-5]). In addition, TN-C can also facilitate cell migration and proliferation ([@b18-molcell-37-2-118-5]). In the last decade, it has been demonstrated that tenascin-C plays a vital role in cardiac and arterial injury, tumor angiogenesis and metastasis ([@b17-molcell-37-2-118-5]). A recent study also showed that tenascin-C knock-down in the human LN229 GBM cell line had no significant effect on cell proliferation *in vitro* but abolished cell migration by promoting focal adhesion disassembly signals ([@b8-molcell-37-2-118-5]; [@b17-molcell-37-2-118-5]).

Tenascin-C is composed of four distinct domains: an assembly domain, a series of epidermal growth factor-like repeats (EGF-L), a series of fibronectin type III-like repeats (FNIII), and a C-terminal globular domain homolog to fibrinogen β- and γ-chains ([@b16-molcell-37-2-118-5]; [@b17-molcell-37-2-118-5]). The alternatively spliced FNIII repeats, which includes A1--A4, B, AD2, AD1, C and D subdomains in turn, were shown to promote the migration of cardiac fibroblasts, suggesting that this domain is responsible for the observed tenascin-C effect ([@b17-molcell-37-2-118-5]; [@b29-molcell-37-2-118-5]). Among these domains, FNIIIA1 participate in inhibiting lymphocyte activation, tumor infiltrating lymphocytes and proliferation, as well as blocking the secretion of cytokines ([@b16-molcell-37-2-118-5]).

There are many factors which have been shown to facilitate tenascin-C expression, including growth factors, oxidative stress, inflammatory cytokines and mechanical stress ([@b31-molcell-37-2-118-5]). Among these factors, research has shown that mechanical stimulation is necessary for normal skeletal development. Reduced loading due to long-term bed rest, cast immobilization, or microgravity conditions induces significant bone loss and mineral changes, which only begin to be recovered following the reintroduction of normal activity ([@b5-molcell-37-2-118-5]). However, it remains unknown whether mechanical stimulation can promote MG-63 cells migration through facilitating the overexpression of FNIIIA1 of tenascin C. In this study, we chose osteosarcoma tissue and the MG-63 cell line to explore the effect of mechanical stress on the migration of MG-63 cells. Our results suggest that FNIIIA1 exhibits high expression in osteosarcoma tissue and facilitates the migration of MG-63 cells. Furthermore, with the action of mechanical stress, overexpression of FNIIIA1 was achieved by mTOR, 4EBP1 and S6K1.

MATERIALS AND METHODS
=====================

Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), TRIzol, silicone membrane and Lipofectamine^™^ 2000 were purchased from Invitrogen Life Technologies (USA). Anti-β-actin antibody was purchased from Santa Cruz Biotechnology (USA). Bovine serum albumin (BSA), PVDF membranes, protease inhibitor cocktail, RNase inhibitor, Tween20, RIPA buffer, ascorbic acid, Harris hematoxylin solution, gentamicin, penicillin, mitomycin C and Goat serum were purchased from Sigma-Aldrich (USA). GeneSilencer siRNA transfection reagent was purchased from Gene Therapy System (USA). DNase, RT-PCR kit, and Qiagen RNeasy kit were purchased from Qiagen (Hilden, Germany). LumiGLo reagent and enhanced chemiluminescence (ECL) were purchased from Thermo Pierce (USA). The SYBR^®^ Green PCR Master Mix was purchased from Applied Biosystems (USA). The Diaminobenzidine (DAB) stain kit was purchased from Vector Laboratories, Inc. (USA). Rapamycin (mTOR inhibitor) was purchased from Cell Signaling Technology Inc. (USA). Trypsin-EDTA solution was purchased from Life Technologies (USA). Pyrobest DNA polymerase and avian myeloblastosis virus (AMV) reverse transcriptase were purchased from Takara Biotechnology (Dalian, China). HRP-conjugated sheep anti-mouse IgG antibody was purchased from Cell Signaling Technology (USA). Enhanced Fluorescent Protein Vector (pEGFP-N1) was purchased from Novagen (USA). Anti-annexin II antibody was purchased from BD Biosciences (USA).

Immunohistochemical analysis
----------------------------

This study was approved by the Ethics Committee of the Fourth Military Medical University in accordance with the Declaration of Helsinki. The 54 osteosarcoma tissue samples and 12 adjacent normal tissue samples were collected from osteosarcoma patients by Tangdu Hospital of the Fourth Military Medical University between May 2008 and February 2012. All of the patients had not received any radiation treatment or chemotherapy before surgery. These tissues were fixed in 30% formalin, dehydrated in ethanol, transparentized in ethanol and dimethylbenzene, and embedded in paraffin wax ([@b35-molcell-37-2-118-5]). All specimens were sliced continuously into 3 μm sections. Paraffin-embedded sections were washed in PBS and blocked with 5% normal goat serum in incubation buffer (0.2% Tween20 and 0.1% BSA in PBS). Incubation with mouse anti-human Tenascin-C FNIII domain A1 antibodies, which were prepared according to the method described previously ([@b34-molcell-37-2-118-5]), was performed in a humidified chamber overnight at 4°C. Sections were subsequently washed in washing buffer (0.5% Tween20 in PBS) and incubated with HRP-conjugated sheep anti-mouse IgG antibodies. A diaminobenzidine (DAB) stain kit was used to detect a positive reaction by producing a brown color.

Culture of MG-63 cells
----------------------

MG-63 cells purchased from the American type culture collection (ACTT) were cultured in DMEM culture solution supplemented with 10% FBS, 50 μg/ml ascorbic acid, 100 μg/ml gentamycin and 100 unit/ml penicillin at 37°C in a humidified atmosphere containing 5% CO~2~. During this process, culture solution was changed every 3 days. Adherent cells were digested by 0.25% Trypsin-EDTA solution when the confluence reaches 90% ([@b2-molcell-37-2-118-5]; [@b29-molcell-37-2-118-5]).

Construction and transfection of tenascin-C FNIII A1 expression vector
----------------------------------------------------------------------

The cDNA of FNIIIA1 was sub-cloned with pyrobest DNA polymerase and inserted into a pEGFP-N1 vector. These vectors were transfected into MG-63 cells using Lipofectamine^™^ 2000 ([@b25-molcell-37-2-118-5]). In addition, MG-63 cells were transferred by pEGFP-N1 using Lipofectamine^™^ 2000 as the control group. All of the cells were used for experiments at 72 h after transfection.

Silencing of tenascin-C FNIIIA1 expression with small interference RNA (siRNA)
------------------------------------------------------------------------------

To design target-specific siRNA, an siRNA that was specific for the FNIIIA1 and a scramble control were designed according to the cDNA sequences using the internet tool of siRNA wizard (InvivoGen). The sequences were: 5′-GAA CCA GGA CAG GAG UAC AAU-3′ (21-nt at position 37--57 relative to the start codon) for the FNIIIA1 and 5′-GGA AAC GAC GGA AAC CAG UUA-3′ (21-nt) for the scramble control. The selected siRNA sequences were also submitted to BLAST searches. The sense and antisense strands with two base overhangs were chemically synthesized and annealed (GeneChem, China). MG-63 cells (6 × 10^5^ cells/ml) were transfected with 2 μg/ml FNIIIA1-siRNA or Scramble siRNA using the GeneSilencer siRNA transfection reagent (GeneTherapy System), according to manufacturer's instructions. Twenty-four hours post-transfection, the cells were washed with PBS ([@b6-molcell-37-2-118-5]).

Cell migration assay
--------------------

Migration studies of MG-63 cells (tenascin-C FNIIIA1 overexpression, tenascin-C FNIIIA1 low expression or normal) were performed as previously described ([@b13-molcell-37-2-118-5]). Cell cultures (2.5 × 10^6^ cells/well) were seeded into 6-well tissue culture plates and were allowed to grow to post-confluence. Two days later, cell proliferation was suppressed by incubation with 10 mg/L mitomycin C for 2 h before the experiment. Then, 2 denuded areas (10 × 5 mm) were made in each well using a custom-designed cell scraper. The MG-63 cells were subsequently allowed to migrate for 12 h. After incubation for the indicated time, the cells were fixed with cold methanol at 4°C for 30 min and were stained with Harris hematoxylin solution at room temperature for 40 min. Migration was quantified by counting the average number of cells that migrated into the denuded area in 5 microscope fields covering the border of the entire denuded area. Each assay was repeated at least 3 times ([@b27-molcell-37-2-118-5]). In addition, tenascin-C FNIIIA1 overexpression MG-63 cells treated with or without anti-annexin II antibody were subject to cell migration assay as described above.

Coating of silicone membranes with collagen and mechanical stress assay
-----------------------------------------------------------------------

Three Dimention collagen cell culture system was established as previously described ([@b33-molcell-37-2-118-5]). In brief, a sterile solution of collagen was neutralized with 0.1% acetic acid and diluted to a final concentration of 150 μg/ml with 0.01 M ice-cold PBS. A 100-μl drop of sterile collagen solution was carefully placed onto the silicone membrane (0.05 U, gloss/gloss) at the bottom of a six-well plate as previously described ([@b10-molcell-37-2-118-5]). Collagen was allowed to adsorb to the silicone membrane at room temperature for 4 h. Before seeding cells, redundant liquid was removed, and collagen-coated wells were kept under a UV lamp (254 nm, 20 W, 15-cm distance) for 30 min until silicone membrane dried.

Specially designed six-well dishes prepared as above covered by MG-63 were mounted onto a vacuum extraction device (Developed by Xi'an Jiaotong University, China). Cells were directly subjected to cyclic strain (10%, 0.2 Hz) for indicated time (0 h, 1 h, 4 h, 8 h, and 12 h). For different experiments, cells were divided into different groups.

Cell interference experiment
----------------------------

In this experiment, we chose 0.2 Hz as the stimulating frequency according to our pre-experiment investigations. The grown MG-63 cells were digested by 0.25% Trypsin-EDTA solution and resuspended in DMEM culture solution. Then, 6 × 10^5^/well MG-63 cells (1 ml) were plated on collagen-coated silicone membrane in 6-well plates per-treated above. The MG-63 cell cultures were divided into 4 groups: control group (cells without any addition) and experimental groups including treatment with mTOR inhibitor, 4E-BP1 siRNA or S6K1 siRNA, respectively. The latter groups were treated differently before receiving mechanical stimulation. After MG-63 cells showed confluence, cells were cultured with serum-free DEME culture solution and 1% BSA for 24 h in order to implement cell synchronization. Then, the plates covered by MG-63 cells were mounted onto the vacuum extraction device. MG-63 cells were directly subjected to mechanical stress (0.2 Hz) for indicated time (0, 1, 4, 8, 12 h) and then were lysed for qRT-PCR and Western blotting to detect the expressions of TN-C FNIIIA1. MG-63 cells at resting were lysed at the same time for detecting TN-C FNIIIA1. The siRNA sequences were synthesized by GeneChem (Shanghai, China) and the sequences identified were as follows: S6K1 siRNA (target sequence: 5′-AAC AGU GGA GAA CUA UUU-3′) and a negative control siRNA (nonspecific target sequence: 5′-AAU AGC GAC UAA ACA CAU CAA-3′); 4E-BP1 siRNA (target sequence: 5′-UCU AUG ACC GGA AAU UCC UGA UGG A-3′) and a negative control siRNA (nonspecific target sequence: 5′-UCU CCA GAA GGC UUA AGU CUU AGG A-3′).

qRT-PCR
-------

Total RNA was extracted with TRIzol and purified with the Qiagen RNeasy kit according to the manufacturer's instructions, followed by treatment with DNase. The levels of gene mRNA transcripts were analyzed by one-step quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using the specific primers and the SYBR^®^ Green PCR Master Mix and RT-PCR kit according to the manufacturer's instructions, on an ABI Prism 7700 Sequence Detection System. Primers specific for human FNIIIA1, A2, A3, A4 of TN-C and β-actin were synthesized by the Shanghai Sangon Biological Engineering and Technology Service (China). The sequences of primers were as follows: 5′-GCT TCC AAG AAA CAC TTC CTA T-3′ (sense-primer) and 5′-CCC GAA GGC TGC CAG GCA CGG TGA G-3′ (anti-sense primer) for Tenascin-C FNIIIA1, 5′-AAC CTC ACC GTG CCT GGC AGC CTT C-3′ (sense-primer) and 5′-CTC CTG GGA CGG TGA GGT TCT GGG C-3′ (anti-sense primer) for Tenascin-C FNIIIA2, 5′-CCA GAA CCT CAC CGT CCC AG-3′ (sense-primer) and 5′-CTG CCA GGA ACC GTG AGA TTG TGA G-3′ (anti-sense primer) for Tenascin-C FNIIIA3, 5′-CAC AAT CTC ACG GTT CCT GGC AGC C-3′ (sense-primer) and 5′-CTG AGG CTG CCA GGC AAC GTG AGG T-3′ (anti-sense primer) for Tenascin-C FNIIIA4. Briefly, 20 μl reactions containing 50 ng of total RNA, 10 μl 2× SYBR Green PCR Master Mix, 6.25 U AMV reverse transcriptase, 10 U RNase inhibitor and 0.1 mM primers were subjected to one cycle of 95°C for 10 min and then 40 cycles of 95°C for 15 s, 56°C for 30 s and 72°C for 45 s. For relative quantification, the levels of individual gene mRNA transcripts were firstly normalized to control β-actin (sense: 5′-CTC CAT CCT GGC CTC GCT GT-3′, anti-sense: 5′-GCT GTC ACC TTC ACC GTT CC-3′). Subsequently, the differential expression of these genes was analyzed by the ΔCt method and expressed as fold-changes ([@b6-molcell-37-2-118-5]; [@b28-molcell-37-2-118-5]).

Western blotting
----------------

MG-63 cells (treatment groups or control groups) were lysed with RIPA buffer. The protein concentration was determined using the BCA assay. The protein lysates (40 μg/lane) were separated by SDS-PAGE on 10% polyacrylamide gels and transferred onto PVDF membranes. After blocking with 0.5% skimmed milk powder in 1× PBS-Tween20, the target proteins were probed with 1:1000 mouse anti-human Tenascin-C FNIII domain A1 or anti-β-actin antibody overnight at 4°C. After washing thrice (10 min/time) with 1× PBS-Tween20, the membranes were incubated with HRP-conjugated sheep anti-mouse IgG antibodies (1:4000 dilution by PBS) at room temperature for 1 h and washed again. The reactive bands were detected by enhanced chemiluminescence (ECL) according to the manufacturer's protocol and the relative levels of each protein to β-actin were analyzed ([@b26-molcell-37-2-118-5]).

RESULTS
=======

Overexpression of TN-C FNIII A1 in OS tissues
---------------------------------------------

Previous studies have shown that matricellular protein tenascin-C (TN-C) is overexpressed in various tumor tissues ([@b1-molcell-37-2-118-5]). However, expression of the FNIII A1 domain of TN-C in tumors is still barely understood, especially in osteosarcoma tissues. In this study, we compared the FNIIIA1 expression between osteosarcoma and adjacent normal tissues by immunohistochemistry. As shown in [Fig. 1](#f1-molcell-37-2-118-5){ref-type="fig"}, the up-regulation of A1 in OS tissues ([Figs. 1B](#f1-molcell-37-2-118-5){ref-type="fig"} and [1C](#f1-molcell-37-2-118-5){ref-type="fig"}) was found to be significant compared with normal tissues ([Fig. 1A](#f1-molcell-37-2-118-5){ref-type="fig"}). This result suggests that TN-C FNIIIA1 is over expressed in OS tissues.

TN-C FNIIIA1 facilitates MG-63 cell migration
---------------------------------------------

The above result indicates that TN-C FNIIIA1 is over expressed in OS tissues. In order to explore the function of A1 for MG-63 cells, we constructed A1-overexpression and A1-knockdown MG-63 cells, and these two cell models were verified by qRT-PCR and Western blotting. As shown in [Fig. 2A](#f2-molcell-37-2-118-5){ref-type="fig"}, the mRNA level of A1 was significantly up-regulated in A1 overexpression MG-63 cells and down-regulated in A1 knockdown MG-63 cells compared with the control group (^\*^P \< 0.05). Also, the same results at the protein level for A1 by western blotting are shown in [Fig. 2B](#f2-molcell-37-2-118-5){ref-type="fig"}.

Then through the cell migration assay, we analyzed the effect of A1 on MG-63 cell migration. Cells migrating into the denuded area were counted at the indicated time. As shown in [Fig. 2C](#f2-molcell-37-2-118-5){ref-type="fig"}, the number of MG-63 cells entering the scratched area increased with time. The cell intensity of the area around scratches decreased and cell spacing became larger with a loss of contact with the neighboring cells due to cell migration over time. In addition, the number of MG-63 cells migrating into the denuded area increased with the order of A1 knockdown MG-63 cells, MG-63 cells at resting (control) and A1 overexpression MG-63 cells ([Fig. 2C](#f2-molcell-37-2-118-5){ref-type="fig"}). These results suggest that TN-C FNIIIA1 can induce MG-63 cell migration.

Previous studies by Chung CY have reported that cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C, and may mediate cellular responses to soluble TN-C in the extracellular matrix. They found that antibodies to annexin II prominently stained the external surface of live endothelial cells and blocked the binding of TN-C FNIIIA-D to the cells ([@b4-molcell-37-2-118-5]). Based on this discovery, we designed another experiment for cell migration assay as described above in order to explore whether can TN-C FNIIIA1 affect MG-63 cell migration though its cell surface annexin II. [Figure 2D](#f2-molcell-37-2-118-5){ref-type="fig"} shows that the migration of TN-C FNIIIA1 overexpression MG-63 cells treated with anti-annexin II antibody is significantly inhibited compared with control group. This result suggest that annexin II is necessary for A1-over-expression mediated MG-63 cells migration, which may be the receptor for the alternatively spliced segment of TN-C FNIIIA1.

Overexpression of TN-C FNIIIA1 in MG-63 cells
---------------------------------------------

Studies have shown that TN-C can facilitate cell migration, with the alternatively spliced FNIII repeats of TN-C being shown to be responsible for this effect ([@b17-molcell-37-2-118-5]; [@b18-molcell-37-2-118-5]; [@b29-molcell-37-2-118-5]). In addition, mechanical stress has been shown to facilitate TN-C expression ([@b31-molcell-37-2-118-5]). In this study, we found that TNC FNIIIA1 was over-expressed in OS tissues. However, it is still unknown whether mechanical stress can influence the expression of A1. In order to clarify this question, we detected variations of A1 expression in MG-63 cells which were exposed to mechanical stress *in vitro*. In this section, we mainly explored the expression of A1 in MG-63 cells under mechanical stress. Analysis of A1 expression by qRT-PCR was as described above. As shown in [Fig. 3](#f3-molcell-37-2-118-5){ref-type="fig"}, the mRNA level of A1 was significantly up-regulated (1 h, 4 h, 8 h and 12 h) compared with 0 h (^\*^P \< 0.05), especially at 12 h. However, there is no significant variation of A2, A3 and A4.

Inhibition of mTOR decreases TN-C FNIIIA1 expression in MG-63 cells
-------------------------------------------------------------------

mTOR is a central controller of cell growth and survival in response to growth factors, cytokines, hormones and nutrients ([@b36-molcell-37-2-118-5]). Studies have shown that genetic aberrations of the PI3K-mTOR pathway are among the most common events in human malignancies, resulting in hyperactivation of mTOR signaling and causing these cancer cells highly addictive to mTOR pathway ([@b37-molcell-37-2-118-5]). mTOR is a PI3K-related kinase that forms two distinct protein complexes called mTORC1 and mTORC2 ([@b19-molcell-37-2-118-5]). In response to upstream stimuli, mTORC1 phosphorylates S6K1 and 4E-BP1 to stimulate protein synthesis ([@b15-molcell-37-2-118-5]; [@b38-molcell-37-2-118-5]).

In order to explore the effect of mTOR on A1 expression, we detected mRNA and protein levels of A1 in MG-63 cells with pretreatment with mTOR inhibitors, mechanical stress, or both, respectively. As shown in [Fig. 4A](#f4-molcell-37-2-118-5){ref-type="fig"}, the mRNA of A1 was signifycantly up-regulated in the group which only received mechanical stress and was down-regulated in the group that was only pretreated by mTOR inhibitor. Both of these groups were compared with the control group (^\*^P \< 0.05), and there was a significant difference also between the two groups (^\#^P \< 0.05). The same results at the protein level by Western blotting are shown in [Fig. 4B](#f4-molcell-37-2-118-5){ref-type="fig"}. These results suggest that mechanical stimulation can promote the expression of A1 in MG-63 cells through mTOR.

Silencing of 4E-BP1 and S6K1 decreases the expression of TN-C FNIIIA1 in different levels
-----------------------------------------------------------------------------------------

The above results indicate that mTOR plays a vital role in the expression of A1 in MG-63 cells which received mechanical stress. Other studies have shown that mTORC1 phosphorylates S6K1 and 4E-BP1 to stimulate protein synthesis. Here, we further explore the role of S6K1 and 4E-BP1 on the expression of A1 mRNA or protein by qRT-PCR or Western blotting, as described above.

A1 mRNA showed the largest expression level when cells received mechanical stress for 12 h, which was chosen for succedent research ([Figs. 3](#f3-molcell-37-2-118-5){ref-type="fig"} and [4](#f4-molcell-37-2-118-5){ref-type="fig"}). MG-63 cells were divided into 4 groups: control group (cells without any treatment) and three experimental groups. The latter includes a group which only received mechanical stress, a group pretreated with 4E-BP1 siRNA and mechanical stress, and a group pretreated with S6K1 siRNA and mechanical stress, respectively. At the mRNA level, the results showed that A1 mRNA was significantly up-regulated in the group which only received mechanical stress. On the contrary, A1 mRNA was significantly down-regulated in the group that was pretreated with S6K1 siRNA and mechanical stress. Both were compared with the control group (^\*^P \< 0.05). Also, A1 mRNA levels in the group pretreated with S6K1 siRNA and mechanical stress were significantly down-regulated compared with those in the group that only received mechanical stress (^\#^P \< 0.05) ([Fig. 5A](#f5-molcell-37-2-118-5){ref-type="fig"}). At the protein level, the expression of A1 was significantly up-regulated in the group that only received mechanical stress and down-regulated in the group pretreated with 4E-BP1 siRNA and mechanical stress as well as the group pretreated with S6K1 siRNA and mechanical stress compared with the control group ([Fig. 5B](#f5-molcell-37-2-118-5){ref-type="fig"}). These results suggest that S6K1 is necessary during A1 mRNA normal expression in MG-63 cells undergoing mechanical stress. However, both 4E-BP1 and S6K1 are necessary during A1 normal expression at the protein level in MG-63 cells experiencing mechanical stress.

DISCUSSION
==========

Osteosarcoma (OS) accounts for \>10% of all solid cancers and 20--35% of all malignant primary bone tumors with a very poor prognosis ([@b3-molcell-37-2-118-5]; [@b23-molcell-37-2-118-5]). Surgery cannot achieve good clinical results because of its highly aggressive nature and the fact that it mostly metastasizes to the bones and lungs ([@b7-molcell-37-2-118-5]). Therefore, treating metastatic osteosarcoma remains a challenge for oncologists. Thus, a novel strategy to efficiently inhibit metastasis of osteosarcoma is highly indispensable.

Tenascin-C belongs to the family of extracellular matrix glycoproteins, which plays a vital role in cardiac and arterial injury, tumor angiogenesis and metastasis ([@b17-molcell-37-2-118-5]; [@b24-molcell-37-2-118-5]; [@b30-molcell-37-2-118-5]). Previous studies have reported the association between TN-C and tumors, and TN-C is known to be overexpressed in various types of tumor cells, such as brain tumors ([@b17-molcell-37-2-118-5]), oral squamous cell carcinoma ([@b22-molcell-37-2-118-5]), and breast cancer ([@b9-molcell-37-2-118-5]).

Studies have demonstrated that mechanical stimulation can facilitate TN-C expression ([@b31-molcell-37-2-118-5]). In addition, TN-C can facilitate cell migration, and the alternatively spliced FNIII repeats of TN-C were shown to responsible for this effect ([@b17-molcell-37-2-118-5]; [@b18-molcell-37-2-118-5]; [@b29-molcell-37-2-118-5]). Meanwhile, domain A1 of FNIII has become a research hotspot for the effect of inhibiting lymphocyte activation, tumor infiltrating lymphocytes, proliferation and blocking the secretion of cytokines ([@b16-molcell-37-2-118-5]). However, it was still unknown whether mechanical stimulation can promote MG-63 cell migration though facilitating the over-expression of TN-C FNIIIA1. To the best of our knowledge, this is the first report to evaluate the usefulness of A1 in the migration of MG-63 cells and its potential role in OS.

Through immunohistochemical analysis, we found that the A1 protein was present at a higher level in tissues of osteosarcoma patients than in adjacent normal tissues in the present study. Therefore, we constructed A1 overexpression and knockdown MG-63 cells, and the effect of this was verified by qRTPCR and Western blotting. Through cell migration assay, we observed that the number of MG-63 cells migrating into the denuded area increased in the order of A1 knockdown MG-63 cells, MG-63 cells at rest and A1 overexpression MG-63 cells. These results suggested that TN-C FNIIIA1 can induce MG-63 cell migration *in vitro* and thus may play a critical role in OS metastasis. In addition, annexin II is a indispensable molecule during A1-overexpression mediated MG-63 cells migration, which may be the receptor for the alternatively spliced segment of TN-C FNIIIA1. In recent years, molecular target therapy has brought about a breakthrough in the treatment of tumors. Results presented in this study demonstrate that domain A1 of TN-C may be a potential therapeutic target in metastatic osteosarcoma. However, the clinical usefulness of A1 in metastatic OS has not been fully described and further studies are needed to define the role of it in OS.

In order to explore the effect of mechanical stress on A1 expression, we carried out mechanical stress experiments. According to our statistical analyses, mRNA levels of A1 compared with other domain of FNIII (A2, A3, A4) were significantly up-regulated with mechanical action time, especially in the 12 h group. This result suggests that mechanical stress derived from the daily activities of OS patients might promote the expression of A1. However, the detailed mechanism and its clinical reliability need to be confirmed. Therefore, we further explored the signaling pathway related to A1 expression and found that the mTOR molecule is indispensable during this procedure. Meanwhile, further research about the effects of 4E-BP1 and S6K1 on A1 expression in MG-63 cells experiencing mechanical stress demonstrated that 4E-BP1 and S6K1, which are downstream molecules of mTOR, are necessary for the normal expression of A1 in MG-63 cells. Therefore, we speculated that mTOR, 4E-BP1 and S6K1 may be involved in the expression of A1. This is consistent with the theory that mTORC1 phosphorylates S6K1 and 4E-BP1 to stimulate protein synthesis ([@b15-molcell-37-2-118-5]; [@b38-molcell-37-2-118-5]).

For a long time, there has been no exercise limitation for OS patients clinically, due to the traditional view that there is no effect of exercise on OS. However, in our research, we demonstrated that mechanical stimulation can promote MG-63 cell migration though facilitating TN-C FNIIIA1 overexpression *in vitro*. This suggests that the daily activities of OS patients may promote the expression of A1, and that the overexpression of A1 in OS tissues may influence OS migration and aggravate OS deterioration. Meanwhile, the results of this study provide the theoretical basis for the effect of A1 on OS migration in further clinical research. However, the clinical inhibition of activities in OS patients need to be further studied.

In conclusion, the high expression of A1 was correlated with MG-63 cell migration, suggesting that A1 could be used as an indicator in metastatic osteosarcoma patients. Our results might provide a novel way to explore targeted therapy in OS patients. Furthermore, the effect of activities of OS patients on OS metastasis need further research.
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![Overexpression of TN-C FNIIIA1 in OS tissues. TN-C FNIIIA1 in the extracellular matrix (ECM) of normal tissues and OS tissues was detected by Immunohistochemistry staining. (A) normal tissue; (B) OS tissue; (C) OS tissue. Brown color indicates positive expression of A1. Magnification, ×40.](molcell-37-2-118-5f1){#f1-molcell-37-2-118-5}

![TN-C FNIIIA1 facilitates MG-63 cell migration. The pEGFPN1-TN-C FNIIIA1 recombinants was transfected into MG-63 cells by liposome transfection. And A1 knockdown MG-63 cells were constructed by RNA interference. A1 expressions in these cells were verified by qRT-PCR and Western blotting, and cellular mig-ration abilities were detected by cell migration assay. Data were normalized based on the β-actin levels. (A) The expression of A1 mRNA by qRT-PCR. ^\*^P \< 0.05 by Student's test when compared with control group; (B) The protein level of A1 by Western blotting. Besides, the effect of A1 on MG-63 cell migration was detected by cell migration assay. (C) The number of MG-63 cells migrating into the denuded area. (D) The number of TN-C FNIIIA1 overexpression MG-63 cells migrating into the denuded area.](molcell-37-2-118-5f2){#f2-molcell-37-2-118-5}

![The mRNA level of A1 is elevated in MG-63 cells under mechanical stress. Expression of A1 in MG-63 cells was detected by qRT-PCR under different stimulation time for 1 h, 4 h, 8 h, and 12 h, respectively. Same experiments were carried out to detect A2, A3 and A4, which are the alternatively spliced FNIII repeats. Data were normalized based on the β-actin levels. ^\*^P \< 0.05 by Student's test when compared with control group.](molcell-37-2-118-5f3){#f3-molcell-37-2-118-5}

![Inhibition of mTOR decreases expression of TN-C FNIIIA1. A1 mRNA and protein expression in MG-63 cells treated by different conditions (mechanical stress, mTOR inhibitor or both) as measured by qRT-PCR and Western blotting. Data were normalized based on the β-actin levels. (A) The expression of A1 mRNA under different conditions by qRT-PCR. ^\*^P \< 0.05 and ^\#^P \< 0.05 by Student's test when compared with control group and group only received mechanical stress, respectively. (B) The protein level of A1 under different conditions by Western blotting.](molcell-37-2-118-5f4){#f4-molcell-37-2-118-5}

![Silencing of 4E-BP1 and S6K1 decreases expression of TN-C FNIIIA1 in different levels. A1 mRNA and protein expression in MG-63 cells treated by different conditions (treated with mechanical stress only, treated with 4E-BP1 siRNA and mechanical stress, or treated with S6K1 siRNA and mechanical stress) were measured by qRT-PCR and Western blotting. Data were normalized based on the β-actin levels. (A) The expression of A1 mRNA in MG-63 cells treated by different conditions. ^\*^P \< 0.05 and ^\#^P \< 0.05 by Student's test when compared with control group and group only received mechanical stress, respectively. (B) The expression of A1 in MG-63 cells treated by different conditions as detected by Western blotting.](molcell-37-2-118-5f5){#f5-molcell-37-2-118-5}
